

Reference number(s)
7310-A

# Specialty Guideline Management Redemplo

## Products Referenced by this Document

Drugs that are listed in the following table include both brand and generic and all dosage forms and strengths unless otherwise stated. Over-the-counter (OTC) products are not included unless otherwise stated.

Brand Name	Generic Name
Redemplo	plozasiran

## Indications

The indications below including FDA-approved indications and compendial uses are considered a covered benefit provided that all the approval criteria are met and the member has no exclusions to the prescribed therapy.

### FDA-approved Indications<sup>1</sup>

Redemplo is indicated as an adjunct to diet to reduce triglycerides in adults with familial chylomicronemia syndrome (FCS).

## Documentation

Submission of the following information is necessary to initiate the prior authorization review:

### Initial requests:

- Genetic test(s) confirming diagnosis of FCS.
- Chart notes or medical record documentation indicating North American familial syndrome (NAFCS) score or Moulin score (if applicable).
- Laboratory tests or medical record documentation of fasting triglycerides (TG) level.

Reference number(s)
7310-A

## Continuation requests:

- Chart notes or medical record documentation supporting positive clinical response.

## Prescriber Specialties

This medication must be prescribed by or in consultation with a cardiologist, endocrinologist, lipid specialist, geneticist, or a prescriber specialized in the treatment of FCS.

## Coverage Criteria

### Familial chylomicronemia syndrome (FCS)<sup>1-9</sup>

Authorization of 12 months may be granted for treatment of familial chylomicronemia syndrome (FCS) (type 1 hyperlipoproteinemia) in adult members when all of the following criteria are met:

- Member meets either of the following:
  - Member has a confirmed FCS diagnosis by genetic testing (i.e., biallelic pathogenic variants in FCS-causing genes [e.g., LPL, GPIHBP1, APOA5, APO2, LMF1, GPD1, CREB3L3]).
  - Genetic testing was inconclusive, and the member has confirmed FCS diagnosis by either of the following:
    - North American familial chylomicronemia syndrome (NAFCS) score greater than or equal to 45.
    - Moulin score greater than or equal to 10.
- Member has a fasting triglycerides (TG) level of more than or equal to 880 mg/dL.
- Member is currently receiving a very-low fat diet (e.g., less than 20 to 30 g of total fat per day, 10% to 15% of calories of fat).
- Member will not use the requested medication concomitantly with Tryngolza.

## Continuation of Therapy

Authorization of 12 months may be granted for continued treatment in adult members requesting reauthorization for FCS when both of the following criteria are met:

- Member has demonstrated a positive clinical response with the requested medication (e.g., reduction in TG level from baseline, reduction in episodes of acute pancreatitis).
- Member is currently receiving a very-low fat diet (e.g., less than 20 to 30 g of total fat per day, 10% to 15% of calories per day of fat).

Reference number(s)
7310-A

- Member will not use the requested medication concomitantly with Tryngolza.

## References

1. Redemplo [package insert]. Pasadena, CA: Arrowhead Pharmaceuticals, Inc.; November 2025.
2. Watts GF, Rosenson RS, Hegele RA et al. Plozasiran for managing persistent chylomicronemia and pancreatitis risk. *N Engl J Med.*2025; 392 (2): 127-137.
3. Falko JM. Familial chylomicronemia syndrome: a clinical guide for endocrinologists. *Endocr Pract.* 2018;24(8):756-763.
4. Hegele RA, Boren J, Ginsberg HN, et al. Rare dyslipidaemias, from phenotype to genotype to management: a European Atherosclerosis Society task force consensus statement. *Lancet Diabetes Endocrinol.* 2020;8(1):50-67.
5. Spagnuolo CM, Hegele RA. Etiology and emerging treatments for familial chylomicronemia syndrome. *Expert Rev Endocrinol Metab.* 2024;19(4):299-306.
6. Javed F, Hegele RA, Garg A et al. Familial chylomicronemia syndrome: An expert clinical review from the National Lipid Association. *J Clin Lipidol.*2025; 19:382-403.
7. Hegele RA, Ahmad Z, Ashraf A, et al. Development and validation of clinical criteria to identify familial chylomicronemia syndrome (FCS) in North America. *J Clin Lipidol.* 2025;19(1):83-94.
8. Moulin P, Dufour R, Averna M, et al. Identification and diagnosis of patients with familial chylomicronaemia syndrome (FCS): expert panel recommendations and proposal of an “FCS score”. *Atherosclerosis.* 2018;275:265-272.
9. Brown AS, Moulin P, Dibble A et al. Brief communication: Strong concordance of the North American Familial Chylomicronemia Syndrome Score with a positive genetic diagnosis in patients from the Balance study. *J Clin Lipidol.* 2025; 11(16): 1-6.